Cover Image
Market Research Report

Global Human Microbiome Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 599236
Published Content info 106 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Human Microbiome Therapeutics Market 2018-2022
Published: December 27, 2017 Content info: 106 Pages
Description

About Human Microbiome Therapeutics

Microbiome Therapeutics is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. GIT is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.

Technavio's analysts forecast the global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global human microbiome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of human microbiome therapeutics.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Human Microbiome Therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ENTEROME Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences

Other Prominent Vendors

  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Takeda Pharmaceutical

Market driver

  • Side effects of the existing treatments
  • For a full, detailed list, view our report

Market trend

  • Growing investments from venture capitalists
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR20038

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market size and forecast

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY THERAPEUTIC APPLICATION

  • Comparison by therapeutic application
  • Gastrointestinal disorders
  • Immunological conditions
  • Others
  • Market opportunity by therapeutic application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Comparison by region
  • Human microbiome therapeutics market in Americas
  • Human microbiome therapeutics market in EMEA
  • Human microbiome therapeutics market in APAC
  • Key leading countries
  • Market opportunity by region

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Increase in industry-academia collaboration
  • Increasing investments by venture capitalists

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive analysis

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ENTEROME Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Microbiome by host
  • Exhibit 02: Common prebiotics
  • Exhibit 03: Major sources of prebiotics
  • Exhibit 04: Benefits of probiotics
  • Exhibit 05: Parent market
  • Exhibit 06: Global human microbiome therapeutics market: Characteristics
  • Exhibit 07: Global human microbiome therapeutics market: Segmentation
  • Exhibit 08: Market definition: Inclusions and exclusions checklist
  • Exhibit 09: Market size 2017
  • Exhibit 10: Validation techniques employed for market sizing 2017
  • Exhibit 11: Global human microbiome therapeutics market 2017-2022 ($ millions)
  • Exhibit 12: Global human microbiome therapeutics market: Year-over-year growth
  • Exhibit 13: Five forces analysis 2017
  • Exhibit 14: Five forces analysis 2022
  • Exhibit 15: Bargaining power of buyers
  • Exhibit 16: Bargaining power of suppliers
  • Exhibit 17: Threat of new entrants
  • Exhibit 18: Threat of substitutes
  • Exhibit 19: Threat of rivalry
  • Exhibit 20: Market condition: Five forces 2017
  • Exhibit 21: Pipeline landscape
  • Exhibit 22: Key clinical trials
  • Exhibit 23: Global human microbiome therapeutics market by therapeutic application 2017-2022 (% share)
  • Exhibit 24: Comparison by therapeutic application
  • Exhibit 25: Global human microbiome therapeutics market by gastrointestinal disorders 2017-2022 ($ millions)
  • Exhibit 26: Global human microbiome therapeutics market by gastrointestinal disorders: Year-over-year growth 2018-2022
  • Exhibit 27: Global human microbiome therapeutics market by immunological conditions 2017-2022 ($ millions)
  • Exhibit 28: Global human microbiome therapeutics market by immunological conditions: Year-over-year growth 2018-2022
  • Exhibit 29: Global human microbiome therapeutics market by others 2017-2022 ($ millions)
  • Exhibit 30: Global human microbiome therapeutics market by others: Year-over-year growth 2018-2022
  • Exhibit 31: Market opportunity by therapeutic application
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global human microbiome therapeutics market by region 2017-2022 (% share)
  • Exhibit 34: Regional comparison
  • Exhibit 35: Human microbiome therapeutics market in Americas 2017-2022 ($ millions)
  • Exhibit 36: Human microbiome therapeutics market in Americas: Year-over-year growth
  • Exhibit 37: Human microbiome therapeutics market in EMEA 2017-2022 ($ millions)
  • Exhibit 38: Human microbiome therapeutics market in EMEA: Year-over-year growth 2018-2022
  • Exhibit 39: Human microbiome therapeutics market in APAC 2017-2022 ($ millions)
  • Exhibit 40: Human microbiome therapeutics market in APAC: Year-over-year growth 2018-2022
  • Exhibit 41: Top Asian countries in terms of population with diabetes (millions)
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity by region
  • Exhibit 44: Global obesity facts 2014
  • Exhibit 45: Factors causing changes in human microbiome
  • Exhibit 46: Antibiotic resistance steps
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Competitive structure analysis of global microbiome therapeutics market
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: ENTEROME Bioscience: Overview
  • Exhibit 54: ENTEROME Bioscience: Business segments
  • Exhibit 55: ENTEROME Bioscience: Organizational developments
  • Exhibit 56: ENTEROME Bioscience: Geographic focus
  • Exhibit 57: ENTEROME Bioscience: Segment focus
  • Exhibit 58: ENTEROME Bioscience: Key offerings
  • Exhibit 59: Rebiotix: Overview
  • Exhibit 60: Rebiotix: Business segments
  • Exhibit 61: Rebiotix: Organizational developments
  • Exhibit 62: Rebiotix: Geographic focus
  • Exhibit 63: Rebiotix: Segment focus
  • Exhibit 64: Rebiotix: Key offerings
  • Exhibit 65: Seres Therapeutics: Overview
  • Exhibit 66: Seres Therapeutics: Business segments
  • Exhibit 67: Seres Therapeutics: Organizational developments
  • Exhibit 68: Seres Therapeutics: Geographic focus
  • Exhibit 69: Seres Therapeutics: Segment focus
  • Exhibit 70: Seres Therapeutics: Key offerings
  • Exhibit 71: Vedanta Biosciences: Overview
  • Exhibit 72: Vedanta Biosciences: Business segments
  • Exhibit 73: Vedanta Biosciences: Organizational developments
  • Exhibit 74: Vedanta Biosciences: Geographic focus
  • Exhibit 75: Vedanta Biosciences: Segment focus
  • Exhibit 76: Vedanta Biosciences: Key offerings
Back to Top